期刊文献+

载体介导的RNA i技术对HL-60细胞端粒酶逆转录酶基因表达和细胞增殖的影响

Effect of hTERT gene expression and activity of proliferation on HL-60 cell line by vector-based RNAi technology
下载PDF
导出
摘要 目的探讨由载体介导的靶向端粒酶逆转录酶(hTERT)基因的RNA i技术对人类髓系白血病HL-60细胞hTERT基因表达和细胞增殖的影响。方法用表达针对hTERT基因siRNA的质粒载体转染HL-60细胞,以转染后24、72、120 h细胞组作为3个实验组,以空质粒组、转染试剂组及空白对照组作为3个对照组,RT-PCR法检测HL-60细胞hTERT基因mRNA的表达,MTT法检测HL-60细胞增殖活性。结果转染后24、72、120 h组HL-60细胞hTERT基因mRNA相对表达水平分别为0.31±0.08、0.28±0.05、0.32±0.06,质粒组、转染试剂组、空白对照组分别为0.55±0.13、0.49±0.08、0.58±0.19,3个实验组HL-60细胞hTERT mRNA表达水平低于3个对照组,差异有显著性(P<0.05),3个实验组组间比较差异无显著性(P>0.05),3个对照组间表达水平比较差异无显著性(P>0.05);24、72、120 h实验组细胞增殖活性抑制率分别为(23.7±4.0)%、(35.1±5.9)%、(29.6±3.8)%,质粒组分别为(3.7±0.8)%、(2.1±0.5)%、(2.7±0.9)%,转染试剂组分别为(4.0±1.8)%、(2.6±1.3)%、(2.2±1.1)%,空白对照组均为0,3个实验组HL-60细胞增殖活性抑制率明显高于各对照组,差异有显著性(P<0.05),3个实验组及组间比较差异无显著性(P>0.05),3个对照组组间比较差异无显著性(P>0.05)。结论载体介导的靶向hTERT基因的RNA i技术能在体外抑制HL-60细胞hTERT基因的表达,细胞增殖活性受抑制。 Objective To explore the effect of RNAi technology targeting hTERT by vector on hTERT mRNA expression and the antiproliferative effects of HL-60 cells.Methods hTERT-siRNA plasmid was transfected into HL-60 cells by RNAi-Mate.The empty plasmid,transfected reagent and blank groups were used as controls.Cells were collected at 24,72,120 h,respectively.After transfection,the expression of hTERT mRNA and the antiproliferative effects of cells were detected by RT-PCR and MTT assay.Results hTERT mRNA expression of test groups at 24,72,120 h were 0.31±0.08,0.28±0.05 and 0.32±0.06 respectively,while the expression level of empty plasmid,transfected reagent and blank groups were 0.55±0.13,0.49±0.08,0.58±0.19 respectively.Compared with control groups,hTERT mRNA expression in test groups was significantly lower(P0.05);there were no significant differences among three test groups(P0.05);compared with blank group,hTERT mRNA expressions in the empty plasmid and transfected reagent groups had no significant differences(P0.05).The antiproliferative effects of RNAi in HL-60 cells in 24 h,72 h,120 h test groups were(23.7±4.0)%,(35.1±5.9)%,(29.6±3.8)%,respectively;they were(3.7±0.8)%,(2.1±0.5)%,(2.7±0.9)% in the empty plasmid group and(4.0±1.8)%,(2.6±1.3)%,(2.2±1.1)% in transfected reagent group.The antiproliferative effects of cells in test groups were higher than that in control groups(P0.05);there were no distinguished differences among three test groups(P0.05);compared with blank group,the antiproliferative effects in the empty plasmid and transfected reagent groups had no distinguished differences(P0.05) in 24 h,72 h,120 h.Conclusion RNAi technology targeting hTERT by vector could inhibit the expression of hTERT gene and the activity of HL-60 cells proliferation in vitro.
出处 《中国小儿血液与肿瘤杂志》 CAS 2011年第2期78-81,共4页 Journal of China Pediatric Blood and Cancer
关键词 端粒酶逆转录酶 RNA干扰 白血病 基因表达 增殖活性 hTERT RNAi Leukemia Gene expression Proliferation activity
  • 相关文献

参考文献13

  • 1毛立军,郑骏年,李望,郑宏祥,刘俊杰,孙晓青,陈家存,温儒民.人端粒酶逆转录酶基因RNAi表达载体的构建、鉴定[J].徐州医学院学报,2006,26(1):37-39. 被引量:4
  • 2李登举.端粒酶与细胞周期、细胞凋亡及癌基因的关系[J].国外医学(分子生物学分册),2001,23(2):86-88. 被引量:10
  • 3Scherer LK,,Rossi JJ.Recent applications of RNAi in mammaliansystems. Current Pharmaceutical Biotechnology . 2004
  • 4Devi GR.siRNA-based approaches in cancer therapy. Cancer Gene Therapy . 2006
  • 5CM Counter.The roles of telomeres and telomerase in cell life span. Mutation Research . 1996
  • 6Cioca DP,Aoki Y,Kiyosawa K.RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines. Cancer Gene Therapy . 2003
  • 7Fire A,Xu S,Montgomery MK,et al.Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature . 1998
  • 8Izquierdo M.Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Therapy . 2005
  • 9Bertrand J R,Pottier M,Vekris A,et al.Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochemical and Biophysical Research Communications . 2002
  • 10Bodnar A G,Ouellette M,Frolkis M,et al.Extension of life-span by introduction of telomerase into normal human cells. Science . 1998

二级参考文献22

  • 1[1]Perrem K et al.Oncogene,1999 ;18:3383
  • 2[2]Aldous WK et al.Cancer,1999;85:1523
  • 3[3]Akiyama M et al.Cancer Lett,1999; 142:23
  • 4[4]Sharma S et al.Leu Res,1998; 22:663
  • 5[5]Kusumoto M et al.Clin Cancer Res,1999; 5:2140
  • 6[6]Landerg G et al.Cancer Res,1997; 57:549
  • 7[7]Balasubramamanian S et al.Oncogene,1999;18:1297
  • 8[8]Greenberg RA et al.Cell,1999; 97:515
  • 9[9]Sawa H et al.J Neurooncol,1999; 42:45
  • 10[10]Terasaki M et al.Int J Oncol,1999; 14:63

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部